GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Inventories, Inventories Adjustments

Tvardi Therapeutics (LTS:0HTC) Inventories, Inventories Adjustments : £-1.17 Mil (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Inventories, Inventories Adjustments?

Tvardi Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2025 was £-1.17 Mil.

Tvardi Therapeutics's quarterly Inventories, Inventories Adjustments stayed the same from Mar. 2024 (£0.00 Mil) to Sep. 2024 (£0.00 Mil) but then declined from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£-1.17 Mil).


Tvardi Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Tvardi Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Inventories, Inventories Adjustments Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
Inventories, Inventories Adjustments
- -

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
Inventories, Inventories Adjustments - - - - -1.17

Tvardi Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Tvardi Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines